Jetrea – Now Available
Jetrea is the first and only eye medicine to treat sight-threatening, symptomatic vitreomacular adhesion affecting an estimated 15,000 Canadians each year.
Vitreomacular adhesion occurs when the gel inside the eye starts to pull on the retina. In doing so, vision can be distorted or blurred. If patients are affected by this and it doesn’t resolve on its own, Jetrea can be injected by a retinal ophthalmologist.
Jetrea is an active enzyme that works to break down the protein fibres that cause the abnormal pull between the gel inside the eye and the retina.
Last evening, all the doctors at Abbey Eye Care attended a talk hosted by Alcon Canada and Dr. Varun Chaudhry. Dr. Chaudhry discussed the criteria that make certain patients candidates for this new medical treatment. Several case studies of actual patients that underwent treatment with Jetrea were also discussed.
